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 Lyme disease is the most commonly reported vector-borne disease in the United 
States. Although most patients respond well to antibiotic treatment, 10-20% suffer 
chronic symptoms of carditis, arthritis, and neurological impairment months after 
treatment. The cause of these symptoms is still undetermined, but there are many theories 
to explain this phenomena including autoimmune activation, the presence of antigenic 
debris, and treatment-resistant persistent bacteria. Evidence of treatment-resistant and 
non-culturable Borrelia has been seen in animals, but these results remain controversial.  
Orally available, low toxicity drugs were tested in combination against Borrelia 
burgdorferi in vitro to determine if combined use would increase their activity. These 
combinations were tested against both stationary phase and persistent bacteria using a 
SYBR Green I/PI rapid viability assay, and were confirmed via epifluorescent 
microscopy. Several trends were seen among high activity combinations. Triple drug 
combinations including cefuroxime, a protein synthesis inhibitor [doxycycline, 
azithromycin, nitrofurantoin, etc.], and a free radical producing drug [methylene blue, 
artemisinin, etc.] had the highest activity against stationary phase cultures. However, 
drug combinations targeting DNA transcription [rifabutin] and either membrane 
permeability or homeostasis mechanisms [fluconazole, hydroxychloroquine, etc.] were 
highly effective against amoxicillin-treated persisters. These results suggest these 
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Borrelia burgdorferi sensu stricto is the causative agent of Lyme disease, the 
most commonly reported vector-borne disease in the United States.2 Lyme disease has an 
incidence rate of 8.6 confirmed cases per 100,000 people in the US, though recent reports 
have suggested that unreported cases may be as high as 300,000 a year.1,2 The incidence 
of reported Lyme cases in endemic regions has increased steadily from 1992 to 2006, and 
this trend is expected to continue.3 The number of infections in the United States is 
expected to increase in the coming years, causing this disease to be an emerging public 
health threat. 
Lyme disease does not have a uniform geographic transmission, but instead is 
found in a scattered distribution of highly endemic foci.4 Disease transmission is 
seasonal, with the majority of reported cases occurring between June and August.3 This 
seasonality is likely the result of both an increase in tick foraging behavior and exposure 
to human hosts during these months. Various environmental factors such as the projected 
increase in temperature and humidity during winter and spring months is expected to 
result in a longer disease transmission window and the expansion of Lyme foci into new 
geographic regions.5 This disease expansion is projected to increase the amount of 
infections in the United States in the upcoming years.  
Lyme disease is vectored by members of the Ixodes tick family and is transmitted 
to humans from rodents, birds, and various small mammals depending on the geographic 
region.6 As the Ixodes ticks undergo multiple developmental stages from nymph to adult, 
they are able to maintain infection with Borrelia burgdorferi transstadially.7 However, 





the nymphal and larval ticks must acquire the bacteria through a blood meal taken from a 
previously infected host.8 The bacteria can then be transferred to human hosts during 
blood feeding by an infected tick.  
Each Lyme endemic geographic foci has a slightly different enzootic disease 
cycle. The first discovered Lyme endemic foci is in the Northeast United States, where 
the transmission occurs between Maine and Maryland, as well as in Wisconsin and 
Minnesota.4 The primary vector in this area is the deer tick Ixodes scapularis. In this 
region, nymphal ticks transmit the infection primarily through white-footed mice and 
chipmunks, maintaining the disease enzootically.6 The adult Ixodes ticks feed primarily 
on larger mammals such as humans and deer, which are both incidental hosts and cannot 
further the disease transmission cycle.6 Despite the presence of incidental hosts in this 
cycle, this enzootic cycle is very efficient and results in the highest rates of Borrelia 
infection in ticks among the endemic foci in the US. 
 In the Pacific Northwest, the primary tick responsible for human infection is the 
Ixodes pacificus.4 In comparison to the Ixodes scapularis, this tick population tends to 
have lower infection rates, resulting in lower levels of Lyme disease in this region.4 The 
primary vectors and hosts for the Lyme disease life cycle in Europe and Asia are still 
uncertain, as the ticks in these regions tend to feed on a variety of hosts and show less 
species-specific feeding than the American tick species.4   
Our current ability to accurately diagnose Lyme disease is suboptimal, resulting in 
confusion over diagnoses and a likely underreporting of case numbers. This diagnostic 
difficulty is partially due to the multi-stage nature of this disease, as each stage requires 





disease infection can be diagnosed clinically, often through the presence of a 
characteristic rash known as an erythema migrans.9 Clinicians use a variety of methods to 
diagnose later stages of Lyme disease, but there is debate about the accuracy of these 
methods.  
While most bacterial infections are traditionally diagnosed via bacterial culture, 
this method is not feasible for Lyme disease in many clinics due to the low yield from 
patient samples and long culture times.10 The best results from bacterial culture occur 
when the sample is collected directly from the erythema migrans, but even this yields 
highly variable results, with successful culturing occurring only 5-43% of the time.11 
Culturing the bacteria from patient blood or synovial fluid has been even less 
successful.11 A clinician may also elect to perform a lumbar puncture if they suspect 
neurological involvement or to rule out other infections.12 These samples are often tested 
using polyvalent ELISAs, however the interpretation of these results varies between 
laboratories. According to the guidelines set by the Infectious Disease Society of 
America (IDSA), patients experiencing symptoms for more than 4 weeks must have both 
IgM and IgG Borrelia-specific responses to be considered disease positive.13 However, 
this method is unable to determine if a positive result is due to a current or past infection. 
While researchers routinely use PCR to determine the presence of Borrelia DNA in 
patient samples, this method has not yet been approved for clinical diagnosis.13 
Lyme disease is a multisystem disorder that can affect many parts of the body. In 
the early stages of infection, the bacteria are localized at the cutaneous site of the tick’s 
blood meal where they form a characteristic target-shaped rash called the erythema 





the spirochetes disseminate through the skin, before fading 3-4 weeks later regardless of 
treatment.9 Despite the use of this rash for clinical diagnosis, only 50-75% of patients will 
exhibit this characteristic symptom, complicating their Lyme diagnosis.14 At this early 
stage of infection the rash is often accompanied by non-specific symptoms such as fever, 
malaise and regional swelling of the lymph nodes, which do not often aide the clinician in 
diagnosis.9  
After early localized infection the patient develops an early stage disseminated 
infection, at which stage the spirochetes have disseminated further from the cutaneous 
injection site. During this stage approximately half of patients will experience multiple 
secondary erythema migrans on the skin, which are usually smaller and have less gradual 
size increase compared to the primary rash.9 It has been shown that Borrelia are also able 
to penetrate the central nervous system at this stage of infection.14 In one study Borrelia 
DNA was found in the cerebrospinal fluid of 2/3 of patients at the early disseminated 
phase.14 As with the central nervous system, Borrelia are able to begin dissemination 
throughout the body at this stage and can infect multiple organs. This results in a variety 
of recurrent symptoms including arthritis, meningitis, carditis, encephalopathy and 
neurological impairment.15 These symptoms often clinically manifest through complaints 
of general malaise, headaches, sore neck and joint pain.15  
Late stage Lyme disease, also called the disseminated stage of infection, occurs 
months to years after the initial infection in patients that were either untreated or 
treatment-resistant.15 Patients with late stage Lyme disease often experience similar 
symptoms to patients with early Lyme disease, however the time between these episodes 





develops in patients with late stage infection, with most of the inflammation occurring 
around major joints, such as the knees.9   
For patients with early stage Lyme disease, antibiotic treatment is typically very 
effective. The treatment for early stage Lyme disease is an antibiotic regimen consisting 
of doxycycline, amoxicillin, or cefuroxime axetil for 10-21 days depending on the 
severity of symptoms.13 In areas with greater than 20% infection rate of Borrelia in the 
tick vectors, doxycycline is also approved for use as a prophylaxis treatment after a 
confirmed tick bite before a positive diagnosis.13 If the patient is unable to take these 
drugs, macrolide antibiotics are generally recommended for use as second line drugs 
only.13 However, Lyme disease patients with cardiac or neurological complications are 
treated ceftriaxone intravenously for 14 days instead of taking the oral regime.13 
 Late stage Lyme patients are treated with the same antibiotic regimen as early 
stage patients, for a longer length of 28 days. However, if these patients have 
neurological involvement, the use of an intravenous beta-lactam antibiotic is 
recommended rather than the oral regime.13 While intravenous antibiotic therapy is more 
expensive and has a higher risk of complications than an oral regime, patients treated 
with intravenous ceftriaxone or penicillin G have been found to be less likely to develop 
neuroborreliosis.13 Due to this finding, patients with serious complications such as 
carditis or neurological impairment are recommended intravenous therapy rather than the 
commonly used oral antibiotics.  
Despite the majority of patients seeing success with the previously outlined 





pain, and neurologic impairment for longer than 6 months after treatment. These patients 
are diagnosed with Post-Treatment Lyme Disease Syndrome (PTLDS), sometimes called 
Chronic Lyme disease, though this diagnosis is still controversial.1,16 Patients who have 
been diagnosed with PTLDS tend to have significantly lower quality of life and 
decreased functional abilities when compared to non-PTLDS Lyme patients.17  
The evidence for Post-Treatment Lyme disease in both humans and animals is 
varied and highly controversial. Laboratory mice have been used as a model for PTLDS, 
as they are a natural host for Borrelia in the wild.18 However, mice do not exhibit the 
same cardiac or arthritic symptoms as humans with chronic Lyme infections, making 
them a suboptimal model for PTLDS.19 Despite dissimilar symptoms, the presence of 
Borrelia DNA was confirmed in the tissue of chronically infected mice up to 9 months 
after treatment via both PCR and xenodiagnoses.19,20 Despite the presence of DNA in 
these mice after treatment, live spirochetes were unable to be cultured from these 
samples.19,20 These results have come under criticism, however, from other groups over a 
lack of standardization of inoculum size, insufficient antibiotic treatment, and other 
methodological concerns.21 
 Further studies in ceftriaxone-treated infected mice have shown that Borrelia 
infections in mice can have a resurgent pattern.22 The treated mice tested consistently 
negative for Borrelia through microscopy, culture, xenodiagnoses and PCR from 1 to 8 
months after infection.22 However, the presence of non-culturable Borrelia was 
discovered in treated mice 12 months after infection through PCR.22 At month 12, the 
levels of Borrelia flaB DNA in the treated mice were similar to the levels found in the 





replicated after antibiotic removal in a form that is not culturable and that mice may be 
used as a viable model for long-term treatment study of PTLDS.      
Evidence of PTLDS in humans has been similarly controversial. One study 
showed culturable Borrelia could be recovered from the blood of 43 out of 47 patients 
presenting with PTLDS symptoms after treatment with a third generation 
cephalosporin.10  Another group were able to culture live Borrelia from patient skin and 
blood samples months after antibiotic treatment.23 However, these results were deemed 
by some to be unrepeatable and no cultures have been reliably grown from patient plasma 
or cerebrospinal fluid samples.10,24 Borrelia DNA has been found to positively correlate 
to active infections, and is cleared from the body quickly following infection, making it a 
positive indicator of active infection.25 Using this marker, Borrelia DNA was found to be 
excreted in patient urine samples previously treated for Lyme disease, indicating the 
possibility of chronic infection.15  
Due to the inconclusive nature of results concerning the existence of PTLDS in 
humans, the IDSA does not officially recognize PTLDS and does not recommend any 
long-term use of antibiotics for treatment.14 The basis for this recommendation comes 
from four studies examining the use of long-term antibiotics to treat patients with PTLDS 
symptoms. Krupp et al. studied the effect of long-term treatment with one month of 
intravenous ceftriaxone on fatigue, mental acuity and clearance of bacterial antigens. This 
study found significant improvement in patient fatigue, but not in the two other criteria 
studied.26 A study by Fallon et al. also examined the effect of intravenous ceftriaxone on 
memory and cognitive function in PTLDS patients with a longer treatment period of 10 





this improvement was not seen upon testing at 14 weeks after treatment. However, this 
study contained only 32 patients, and should be repeated with more participants before 
definitive conclusions can be drawn.27,28 Klempner et al. studied the effect of adding 2 
months of doxycycline treatment to a one month of intravenous ceftriaxone regimen for 
both IgG seropositive and seronegative PTLDS patients. After 180 days, the patients 
were shown to have no significant benefits from the doxycycline treatment.24 However, 
these trials have been criticized for being underpowered and using criteria that exceeded 
the minimum clinically important differences, which could obscure any treatment 
effects.28 All of these studies concluded that the benefits of long-term antibiotic 
treatments for Lyme did not outweigh the risks associated with the treatments.24,26,27 A 
review of all four trials by Delong et al. has deemed these statements to be 
unsubstantiated by these trials, and warns against using these trials to rule out treatment 
possibilities in the clinic.28  
Those who believe in the possibility of PTLDS have developed many theories to 
explain the lack of cultivable cells from these patient samples. It has been suggested that 
the similarity between the Borrelia membrane antigen OspA and the human adhesion 
molecule LFA-1 could result in the activation of the immune system against this self 
LFA-1 antigen and trigger an autoimmune reaction. This theory would explain the 
chronic arthritis often seen in PTLDS, but has been largely discredited as the primary 
reason for PTLDS.29 Others believe that PTLDS symptoms are the result of coinfection 
with other untreated parasitic or bacterial infections such as Babesia, Bartonella 
henselae, and Anaplasma, all of which have been shown to be able to coinfect and be co-





Another theory for PTLDS is the continued presence of antigens in immune 
protected sites in the body. It has been suggested that Borrelia may be able to evade the 
immune system long-term by migrating to immune protected sites such as the central 
nervous system, which would explain the neurologic impairment often associated with 
the disorder.31 Long-term immune evasion is also thought to occur due to altered Borrelia 
morphology in vivo that would alter the ability of the immune system to recognize the 
bacterial antigens through the formation of biofilms or blebbing, both of which 
morphologies can occur in vitro.31  
The most studied theory for the existence of PTLDS symptoms in Lyme patients 
is the role of persistent bacteria that have survived previous antibiotic treatment. 
Persisters are a term used to define a heterogeneous subgroup within a bacterial 
population with phenotypic variants that allow for survival in the presence of antibiotics 
and other stressors while retaining their genetic susceptibility.32 These persistent bacteria 
are thought to be generally dormant in their resistant form, though they can often revert 
back to their original phenotype and resume growth.32 The presence of persistent Borrelia 
in PTLDS patients would explain the presence of bacterial DNA and immune activation 
without the presence of culturable cells, as has been indicated in many studies.15,19,20 One 
study claimed that they were able to grown persistent atypical forms of Borrelia from 60-
80% of PTLDS patient samples using special growth conditions.33 These atypical forms 
of Borrelia were found to be less motile than traditional spirochetes and exhibited 
increased levels of blebbing in vitro.33 
Further studies have linked the morphology of Borrelia to its ability to become 





forms, spheroplast or biofilm-like forms, and round bodies or coccoid forms.34,35 In vitro, 
Borrelia are predominantly spirochetal in growing log phase cultures.34 Once the culture 
reaches stationary phase, the coccoid and biofilm forms became more abundant.34 These 
coccoid forms have also been shown to form in vivo after exposure to Lyme antibiotics.36 
These atypical forms of Borrelia have also been shown to have altered drug 
susceptibilities in vitro, with the coccoid and biofilm-like microcolony forms being the 
least susceptible to antibiotic treatment.34,37 These persistent atypical forms were shown 
to be able to withstand exposure to commonly used Lyme antibiotics at higher 
concentrations than can be achieved clinically.34, 38  
The commonly used Lyme antibiotics have been found to be highly effective 
against actively growing log phase Borrelia cultures, but have little activity against 
stationary phase populations.34 As stationary phase cultures contain higher amounts of 
atypical persistent forms of Borrelia in vitro, these cultures have been used as a model for 
persistent and late stage Lyme infections. However, it is important to note that the age of 
the culture is important in its viability as a model for PTLDS and late stage Lyme 
disease, as persister development in a culture has been shown to be age-dependent.34  
Previous drug screens of a FDA-approved drug library (Johns Hopkins Clinical 
Compound Library version 1.3) and the National Cancer Institute Compound Library 
have been used to identify drugs with higher activity against stationary phase Borrelia 
cultures than the commonly used Lyme antibiotics.34,39 These previous library screens 
identified hits with high activity against stationary phase cultures including daptomycin, 
clofazimine, cefoperazone, sulfa drugs, daunorubicin, mitomycin c, and doxorubicin.34,39 





also have high toxicity and must be administered parentally or intravenously, making 
them both inconvenient and potentially dangerous for use in the currently controversial 
field of PTLDS patient treatment.39 
 In order to address this issue, I chose to examine 13 drugs that were orally 
bioavailable, had low toxicity, and were previously shown to have high activity against 
stationary phase Borrelia populations (<60% viable cells remaining after antibiotic 
exposure).40 These drugs were tested both in double and triple drug combinations in order 
to study the effects of a combinatorial approach to Borrelia antibiotic treatment. The drug 
combinations were tested against both stationary phase Borrelia and persistent Borrelia 
populations, the latter of which was created through previous treatment with amoxicillin. 
Using this method, I was able to examine the activity of these drugs against bacterial 
populations that were partially and fully composed of persistent bacteria in order to gain 
better understanding of which bacterial subpopulation each drug was the most active 
against.  
The use of combination therapy to treat disease is currently being employed in 
many areas, most notably to combat the HIV epidemic, cancer, malaria, and drug-
resistant tuberculosis.41 Along with increased activity against these pathogens, the use of 
multiple drugs is thought to slow the development of genetic drug resistance within a 
population.41 Despite the use of drug combinations in other fields, the use of multiple 
antibiotics against Lyme disease has still not been fully examined, with current IDSA 
guidelines only recommending single drug therapy.13 However, the recommendation 
against the use of drug combinations for Lyme disease is based primarily on lack of 





use of low toxicity drugs that are frequently used effectively in combination for other 
diseases.13  
The International Lyme and Associated Diseases Society (ILADS) has recently 
published their own guidelines for treatment against Lyme disease that differs from the 
IDSA’s.42 This society’s guidelines suggest longer term treatment for early Lyme 
patients, with 4-6 weeks of first line antibiotic treatment rather than the IDSA’s 
recommended 10-21 days.42 This society’s guidelines also suggest continuation of 
treatment until patients are non-symptomatic, and continued long-term antibiotic 
treatment of relapsed Lyme patients.42 Importantly, the ILADS guidelines give clinicians 
more freedom in selecting treatment options, and mention combination antibiotic 
treatments as a possibility for patients not sufficiently treated by long-term single drug 
therapy.42 However, despite this allowance for doctors to prescribe drug combinations to 
Lyme patients, the ILADS does state that there is currently only very low quality 
evidence regarding the efficacy of drug combinations against this disease.42 There is a 
clear need for studies examining the effect of antibiotic drug combinations against 
Borrelia both in vitro and in vivo, a need this study will attempt to fill.  
In order to more closely mirror the effects of these drugs in the human body, the 
chosen drugs were tested as concentrations close to the maximum concentration in patient 
plasma (Cmax). However, it is common practice in drug testing to use a drug 
concentration of at least 2 µg/mL, so any drug that had a lower Cmax value than this 
standard was tested at 2 µg/mL.43 The only drugs that were used at concentrations that 
greatly differed from their Cmax value were daptomycin and the triple combination of 





control. These drugs were previously found to be among the most highly active drugs 
against stationary phase Borrelia populations at the concentration of 10µg/mL.35 
Therefore, the inclusion of these drugs as positive controls in this study allowed for 
comparison between the antibiotic killing of these drug combinations against previously 
published data. 
MATERIALS AND METHODS 
Bacterial strains and culture methods 
Borrelia burgdorferi strain B31 (ATCC35210) was obtained from the American 
Type Tissue Collection (Manassas, VA, USA). All bacteria used in this study were 
passaged no more than 7 times.  The cultures were grown in BSK-H media (HiMedia 
Laboratories, Mumbai, India) supplemented with 6% rabbit serum (Sigma Aldrich, St. 
Louis, MO, USA), that was filter-sterilized using a 0.2 mm filter. The Borrelia cultures 
were incubated in a capped 50 mL conical tube (BD Biosciences, CA, USA) for at least 7 
days at 33°C without shaking, until the culture reached stationary phase. If the culture 
was slow-growing, the transition to stationary phase was determined both visually and 
through the use of microscopic counting. After the culture reached stationary phase, half 
of the 50 mL culture was aliquoted into 96 well plates for drug testing, with 100 µL of 
culture in each desired well. The remaining culture was treated with 6 µg/mL of 
amoxicillin for 6 days to create a culture of persistent Borrelia. After amoxicillin 
treatment the persistent bacterial cell suspension was aliquoted into 96 well plates with 
100µL of cells in each desired well for drug testing, without washing of the bacterial 





Drug Testing against Stationary phase and Persistent Borrelia populations 
The drugs used in the study were diluted from filter-sterilized individual stock 
concentrations. The drugs were diluted so that 2µL of the diluted drug solution added to 
100µL of the bacterial culture would result in the desired drug concentration per well 
shown in Table 1.  For double and triple drug combinations, 2µL of each of the diluted 
drugs were added to 100µL of the bacterial culture in the 96 well plate. After the drugs 
were added to the bacterial cultures in the 96 well plates, the plates were sealed and 
stored in a high humidity environment at 33°C for 7 days without shaking. After 7 days, 
the seal was removed and the culture underwent viability testing. 
SYBR Green I/PI Viability Testing 
The treated bacterial cultures underwent viability testing using a combination of a 
SYBR Green I/PI rapid viability assay along with epifluorescent microscopy, as 
previously described.44 The SYBR Green I/PI assay works as follows: SYBR Green I is a 
green permeant dye that stains all cellular DNA, whereas propidium iodide (PI) is an 
orange-red impermeant dye that stains only the DNA of dead or damaged cells with a 
compromised cell membrane. Thus live or viable cells with intact membranes will be 
stained green by SYBR Green I, while damaged or dead cells with a compromised 
membrane will be stained orange-red by PI. The SYBR Green I/PI assay can be used to 
measure the viability of bacteria in the sample well of 96-well plates. A microplate reader 
is used to measure the green: red fluorescence ratio, which determines the ratio between 
live and dead cells, respectively, in the sample. The viability counts of wells with a 
similar or lower green: red fluorescence ratio than that of the positive control triple drug 





epifluorescent microscopy. Wells that had media discoloration were also confirmed via 
microscopy, as the discoloration was seen to effect the plate-reader determined 
fluorescence ratio.  
Table 
 1. Pharmacokinetics of the drugs screened against stationary phase and persistent 










Artemisinin 0.6 30 2 
Methylene Blue 3.9 72.3 4 
Nitrofurantoin 0.9 90 2 
Azithromycin 0.6 38 2 
Doxycycline 3.17 80 3 
Rifaximin 0.004 0.4 2 
Ciprofloxacin 2.9 79 3 
Rifabutin 1.03 53 2 
Cefuroxime 2.8 68 3 
Pyrimethamine 1.2 90 2 
Clofazimine 1.41 62 2 
Hydroxychloroquine 0.004 74 2 
Fluconazole 6.72 90 6 
Daptomycin 6 NA 10 






The bacterial viability counts were confirmed using 10µL aliquots of treated 
culture from the indicated wells and examined using a Zeiss AxioImager M2 microscope 
and a SPOT slider color camera. Images of three random fields of view were captured for 
each sample to ensure an accurate viability count. These images were quantitatively 
analyzed using Image J software, and the average of the replicate viability counts were 
determined for each sample. All combinations were tested using two different Borrelia 
cultures as replicates. Both cultures were used as soon as they reached stationary phase, 
although differences in growing times meant that the cultures were of different ages when 
tested against the selected drugs. These replicates were both tested against the selected 
drugs both at stationary phase and after a 6-day treatment with 6µg/mL amoxicillin 
without washing to create a persistent population. 
Fluorescence Data Analysis  
The SYBR Green I/PI green: red fluorescence ratios were transformed to cell 
viability counts using the previously published linear regression method.44 In order to 
determine the equation used to transform the raw fluorescence data to residual viable cell 
counts, the fluorescence values of Borrelia cultures with fixed amounts of live: dead cells 
were tested. An aliquot of 7 day old stationary phase Borrelia culture was autoclaved for 
at 121°C for 15 minutes to make a ‘dead’ culture. Samples of this autoclaved culture 
were added to samples taken from the same stock culture at the fixed live: dead ratios of 
0:100, 20:80, 50:50, 80:20 and 0:100µL of live: dead culture. These samples then 
underwent viability testing using the SYBR Green I/PI method and the subsequent green: 





To further ensure accuracy of this cell viability equation, 10µL aliquots from each 
of the live: dead mixed cultures were analyzed using the previously described method for 
epifluorescent microscopy cell viability counting. The raw fluorescence values for each 
live: dead ratio sample were then graphed against the microscopically determined cell 
viability number, and analyzed via linear regression (Figure 1). The equation of that 
linear regression line was then used to transform the rest of the green: red fluorescence 
data into an approximation of their cell viability count without requiring microscopic 
evaluation for each sample. As the drug combinations with the best activity against either 
stationary phase or persister populations were confirmed using microscopic analysis, 
which has been determined to be the most accurate and thorough method for cell viability 
determination, only the microscopic values will be presented in this study for the analysis 
of drug activity against the bacterial populations.  





























Figure 1. Linear relationship between the percent viable Borrelia burgdorferi 
cells and the green: red fluorescence. Fluorescence ratios of live: dead 
Borrelia suspensions measured via the SYBR Green I/PI rapid viability assay, 
and the viability counting performed via epifluorescent microscopy. The 





performed between the fluorescence ratio and the viability cell count. R2 = 
0.9879.  
RESULTS 
   The drug combinations were first screened using the SYBR Green I/PI rapid 
viability assay, the data from which was transformed using linear regression analysis to 
the percentages of residual viable and killed cells remaining after drug treatment for both 
bacterial populations. The combinations that had activity similar to the positive control 
drug combination of daptomycin + cefoperazone + doxycycline were confirmed via 
microscopy.35 Confirmation of a combination’s activity was determined through 
comparison between the cell viability data for two replicates using different bacterial 
cultures of the same culture phase. Only the drug combinations with high enough activity 
to be confirmed via microscopy for both biological replicates against either population 
are presented as a validated hits. In order to account for inter-plate and inter-replicate 
variation, all post-treatment cell viability data was standardized against the cell viability 
data from the no drug control sample for the same plate.  
 Once the drug combinations were confirmed for both replicates, the drugs that 
had a proportion of less than 0.90 residual viable cells remaining when compared to the 
no drug control when analyzed via microscopy, were deemed to be active. Drugs found in 
multiple highly active combinations against a Borrelia population were deemed to be 
highly active against that population. These drugs were then broken down into three 
groups for mechanistic analysis: drugs with high activity against stationary phase 
populations, drugs with high activity against amoxicillin-treated persistent populations, 





Highly Effective Drugs against Stationary Phase Bacteria When Used in 
Combination 
Artemisinin 
Artemisinin is a sesquiterpene lactone whose antimalarial ability results from its 
endoperoxide bridge.41 While artemisinin’s activation mechanism is still unclear, it is 
thought that artemisinin is primarily triggered by the presence of heme. Borrelia have 
been shown by some to accumulate iron intracellularly when grown in a high iron 
environment.45,46  However, recent studies have suggested that Borrelia intracellularly 
aggregate manganese at higher rates than iron. It has also been shown that while these 
bacteria can grow normally in iron-deficient media, the presence of manganese is 
essential for normal bacterial growth and motility. Gene homology also suggests that key 
genes in Borrelia such as SodA and Fur have over 50% homology to manganese-
dependent enzymes in other bacterial species, further suggesting that manganese plays a 
larger role in the function of Borrelia than iron.47 Studies using manganese-containing 
tetraphenylporphyrins as a synthetic heme model have shown that these compounds are 
able to activate artemisinin as effectively as heme.48,49 This suggests that the intracellular 
manganese in Borrelia may be able to activate artemisinin in lieu of endogenous heme. 
 Once activated, artemisinin’s endoperoxide bridge causes the creation of reactive 
oxygen species which can be rearranged into carbon-centered radicals.50 Both species of 
free radicals accumulate in neutrally charged lipids and thiols resulting in lipid 
peroxidation. The free radicals can also cause damage to DNA and metabolic enzymes 
resulting in disruption of DNA transcription and cellular metabolism.51 Artemisinin has 
also been suggested to be involved in protein alkylation, resulting in inhibition of 





Artemisinin is highly effective against stationary phase Borrelia when used in 
triple drug combinations including cefuroxime (Table 2). Cefuroxime, a commonly 
prescribed antibiotic for early Lyme disease, is a second generation cephalosporin that 
functions through the inhibition of cell wall biosynthesis.53,54 Cefuroxime specifically 
disrupts cell wall repair mechanisms by inhibiting the pathways needed for the 
transportation and insertion of peptidoglycan into the cell wall.53,54 Cefuroxime appears 
to complement artemisinin activity for stationary phase Borrelia, likely due to 
cefuroxime’s ability to disrupt the cell wall and allow for increased intracellular 
penetration of artemisinin or through production of reactive oxygen species. 
The triple drug combination of cefuroxime + artemisinin + azithromycin had the 
highest activity against stationary phase Borrelia in this study. Azithromycin is a 
macrolide antibiotic that inhibits bacterial protein synthesis.55 This combination’s high 
antibacterial activity could result from the cell’s inability to repair proteins damaged by 
the free radicals produced by artemisinin. The inhibition of protein synthesis by 
azithromycin could also result in defects in peptidoglycan production, resulting in 
increased penetration of artemisinin into the cells. Artemisinin also showed high activity 
in combination with cefuroxime and nitrofurantoin, a drug that creates electrophiles and 
alters protein function.56 The damage caused by these electrophiles along with an 
inhibition of protein function could also affect mechanisms needed to repair proteins, 








Table 2. Proportion of viable and killed cells after 7-day treatment with high activity 
artemisinin-containing combinations against stationary phase Borrelia burgdorferi when 
compared to no drug control 
















---   
   
Amoxicillin 5 0.97 0.03 0.05      








Artemisinin + Drug treatment 
Cefuroxime + Artemisinin 
















Azithromycin 2 >0.9 <0.1 --- 0.59 0.41 0.00 
Nitrofurantoin 2 >0.9 <0.1 --- 0.73 0.27 0.05 
Fluconazole 6 >0.9 <0.1 --- 0.82 0.18 0.00 
Ciprofloxacin 3 >0.9 <0.1 --- 0.83 0.17 0.05 
Doxycycline 3 >0.9 <0.1 --- 0.85 0.15 0.20 




>0.9 <0.1 --- 0.88 0.12 0.04 
Pyrimethamine 2 >0.9 <0.1 --- 0.89 0.11 0.07 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 






Despite artemisinin’s high activity against stationary phase populations in 
multiple combinations, it was not widely effective against amoxicillin-treated persistent 
populations. However, the triple drug combination of artemisinin + cefuroxime + 
rifabutin did have high activity against persistent Borrelia populations (Table 3). 
Rifabutin, an RNA synthesis inhibitor, functions by blocking the production of RNA. By 
preventing RNA synthesis, the bacteria are no longer able to produce proteins or regulate 
its gene expression to adapt to changing environments. Without the ability to alter gene 
expression in response to cellular damage, the cell would likely be less able to repair the 
damage caused by artemisinin.  
Table 3. Proportion of viable and killed cells after 7-day treatment with high activity 
artemisinin-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 












No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.78 0.22 0.27      








Artemisinin + Drug treatment 
Cefuroxime + 

















Rifabutin 2 >0.9 <0.1 --- 0.69 0.31 --- 
Fluconazole 6 >0.9 <0.1 --- 0.77 0.23 0.07 
Methylene Blue 4 >0.9 <0.1 --- 0.84 0.16 0.25 
Hydroxychloroquine 2 >0.9 <0.1 --- 0.85 0.15 0.30 
Clofazimine 2 >0.9 <0.1 --- 0.85 0.15 0.25 





*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
The other artemisinin-containing drug combination with high activity against 
persisters was the combination of artemisinin + cefuroxime + fluconazole. Fluconazole is 
an antifungal drug that inhibits cytochrome p-450-dependent 14α-sterol demethylase, 
resulting in an inhibition of ergosterol.58 While normally exclusive to fungal membranes, 
Borrelia utilize ergosterol in their membranes to maintain fluidity and membrane 
integrity.59 The membrane dysfunction caused by the addition of fluconazole could allow 
for increased cellular penetration of the other drugs, but it could also function through 
disruption of nutrition uptake. A previous study showed 5 genes encoding ion 
transporters were upregulated in persistent Borrelia, suggesting the importance of 
nutrient uptake in this population.60 The inhibition of ergosterol synthesis could result in 
membrane dysfunction, altering the ability of the persistent cells to uptake nutrients 
necessary for survival in their dormant state. 
Nitrofurantoin 
Nitrofurantoin is a nitrofuran antibiotic commonly prescribed for urinary tract 
infections that functions through the creation of free radicals and protein dysfunction.61 





creation of electrophiles. These reactive species result in the inhibition of components of 
the citric acid cycle, along with causing damage to DNA, RNA and protein synthesis 
mechanisms.55 Nitrofurantoin also functions as a diamide and causes the creation of non-
native disulfide bonds in bacterial proteins, resulting in protein dysfunction. At 
sufficiently high concentrations, nitrofurantoin was also shown in E. coli to completely 
inhibit protein synthesis.55  
Nitrofurantoin is widely effective against stationary phase Borrelia populations 
when used in triple drug combination including cefuroxime (Table 4). The added effect 
of cefuroxime is likely due to an increased ability of the drugs to penetrate the cells, 
especially due to nitrofurantoin’s required intracellular activation. The most effective 
nitrofurantoin combination against stationary phase Borrelia involves artemisinin and 
methylene blue, both drugs implicated in the production of free radicals. As described 
with cefuroxime + artemisinin + azithromycin, the addition of a free radical producing 
drug to a protein disrupting drug appears to be highly effective, likely by preventing the 
repair of damaged cellular proteins.  
Drug combinations including both methylene blue and nitrofurantoin have high 
activity against both stationary phase and persistent Borrelia populations (Table 4) (Table 
5). The addition of cefuroxime to this double drug combination increases the 
combinations’ antibacterial activity against stationary phase populations, but has the 
opposite effect against persisters. Cefuroxime has been shown to have decreased activity 
against dormant cells when compared to growing log phase cells.34 It has been suggested 
that both methylene blue and nitrofurantoin require cellular penetration for full 





methylene blue and nitrofurantoin from entering persisters as readily as stationary phase 
bacteria, which would result in reduced levels of oxidative damage within these cells.   
The triple drug combination of cefuroxime + nitrofurantoin + rifabutin was highly 
effective against amoxicillin-treated persistent populations, while showing little activity 
against stationary phase populations (Table 5). Rifabutin functions through the inhibition 
of DNA transcription, which can result in the inhibition of protein synthesis.63 The highly 
penetrative nature of rifabutin in combination with cefuroxime may allow for the increase 
in penetration necessary for nitrofurantoin to be intracellularly activated in the persistent 
Borrelia populations.63 Once the drugs are activated, the combination of free radicals and 
protein synthesis inhibition likely inhibits the bacteria from repairing the oxidative 


























Table 4. Proportion of viable and killed cells after 7-day treatment with high activity 
nitrofurantoin-containing combinations against stationary phase Borrelia burgdorferi 
when compared to no drug control 












No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.97 0.03 0.05      








Nitrofurantoin + Drug treatment 
Cefuroxime + 

















Methylene Blue 4 0.85 0.15 0.01 0.72 0.28 0.09 
Artemisinin 2 >0.9 <0.1 --- 0.73 0.27 0.05 
Rifabutin 2 >0.9 <0.1 --- 0.75 0.25 --- 
Clofazimine 2 >0.9 <0.1 --- 0.86 0.14 0.03 
Hydroxychloroq
uine 
2 >0.9 <0.1 --- 0.90 0.10 0.03 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 










Table 5. Proportion of viable and killed cells after 7-day treatment with high activity 
nitrofurantoin-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 














0 1.00 0.00 ---   
   
Amoxicillin 5 0.78 0.22 0.27      








Nitrofurantoin + Drug treatment 
Cefuroxime + 

















Rifabutin 2 >0.9 <0.1 --- 0.57 0.43 --- 
Methylene Blue 4 0.74 0.26 0.12 0.78 0.22 0.09 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
Azithromycin 
 Azithromycin is a second-generation macrolide antibiotic derivative of 
erythromycin.54 Azithromycin differs from other macrolides through the presence of 
methyl-substituted nitrogen in its macrolide ring, allowing for increased potency against 





inhibiting the synthesis of fully formed proteins.64,65 Azithromycin has also been 
implicated in biofilm prevention in Pseudomonas aeruginosa, a morphology associated 
with increased levels of persistence in Borrelia populations.66  
 The two drug combinations with the highest activity against stationary phase 
populations include azithromycin and cefuroxime in combination with free radical 
producing drugs methylene blue and artemisinin (Table 6). As azithromycin appears to 
have high activity only when combined with cefuroxime, it is likely that the cefuroxime 
is required for cell wall disruption and increased drug penetration into the cells. The high 
activity against stationary phase populations further suggests the importance of the ability 
of stationary phase Borrelia populations to correct oxidative damage to both DNA and 
proteins intracellularly. Oxidative damage to DNA can result in the accumulation of toxic 
and misfolded proteins, and prevention of necessary cellular functions. The cells also 
require proteins for both maintenance of the cell wall as well as protection of other 
proteins from stress-related damage. Without these proteins, the cellular membrane and 
vital cell functions may be compromised.   
 Despite azithromycin’s high activity against stationary phase populations, the 
drug has less activity against persistent Borrelia populations. Azithromycin only shows 
activity against persistent populations when in combination with hydroxychloroquine or 
methylene blue (Table 7). Methylene blue and azithromycin drug combinations likely 
functions through inhibition of repair mechanisms for damaged proteins. Genes involved 
in maintenance of protein integrity and repair have been found to be upregulated in 





This gene upregulation suggests that protein management is important in persister 
maintenance. 
Table 6. Proportion of viable and killed cells after 7-day treatment with high activity 
azithromycin-containing combinations against stationary phase Borrelia burgdorferi 
when compared to no drug control 












No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.97 0.03 0.05      








Azithromycin + Drug treatment 
Cefuroxime + 

















Artemisinin 2 >0.9 <0.1 --- 0.59 0.41 0.00 
Methylene Blue 4 0.88 0.12 0.11 0.64 0.36 0.13 
Rifabutin 2 >0.9 <0.1 --- 0.78 0.22 --- 
Clofazimine 2 >0.9 <0.1 --- 0.78 0.22 0.02 
Hydroxychloroquine 2 >0.9 <0.1 --- 0.80 0.20 0.01 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 






Table 7. Proportion of viable and killed cells after 7-day treatment with high activity 
azithromycin-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 












No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.78 0.22 0.27      








Azithromycin + Drug treatment 
Cefuroxime + 

















Hydroxychloroquine 2 >0.9 <0.1 --- 0.80 0.20 0.28 
Methylene Blue 4 0.80 0.20 0.23 0.80 0.20 0.15 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
The addition of cefuroxime to this drug combination does not appear to alter the 
antibacterial activity, suggesting that the cefuroxime is neither required for intracellular 
penetration nor does it inhibit the function of methylene blue or azithromycin. It is 
possible that methylene blue’s ability to cause lipid peroxidation provides the necessary 





artemisinin.67 This suggests that membrane penetration may be more important than cell 
wall penetration for antibacterial activity against persistent populations. 
 Hydroxychloroquine is a highly permeant drug that functions through alteration 
of the intracellular pH, which can have deleterious effects on cellular metabolism, DNA 
and proteins.68 While hydroxychloroquine does not create free radicals like methylene 
blue, the rapid alteration of the intracellular pH likely results in the induction of similar 
stress, the repair of which is likely blocked by azithromycin. Stress response mechanisms 
have been found to be vital to persister formation in many different species.69 This 
suggests that the intracellular damage created by these drugs in combination with 
inhibition of possible repair mechanisms may be affecting pathways vital for persister 
cell maintenance and survival.  
Highly Effective Drugs against Both Stationary Phase and Persistent Borrelia When 
Used in Combination 
 
Methylene Blue 
 Methylene blue is the only drug that in the screen with high activity against both 
stationary phase and persistent populations. Methylene blue is a photosensitive dye once 
used as an antimalarial that produces free radicals and hydroxides when exposed to 
light.62 These free radicals cause lipid peroxidation, resulting in the loss of membrane 
integrity, and possibly damage to the peptides in the bacterial cell wall.67 If methylene 
blue is able to penetrate the cell wall, the drug can bind to and modify guanine residues, 
though the effect of this on inhibition of DNA replication has not been determined.70  
 Methylene blue was found to be highly active against stationary phase Borrelia 





stationary phase populations (Table 8). Methylene blue showed significantly higher 
activity against stationary phase populations when used in triple drug combination 
including cefuroxime (p<0.05), though the addition of cefuroxime does not significantly 
increase the combination’s antibacterial activity against persistent populations (p>0.05). 
It has been shown that the addition of amoxicillin to Borrelia populations inhibits cell 
wall synthesis, indicating that the cell walls of persisters may be inherently weaker than 
their stationary phase counterparts.60 This further suggests that cellular wall penetration is 
more important for antibacterial ability against stationary phase than persistent 
populations. 
 Drug combinations including methylene blue had less than 0.90 residual viable 
cells remaining compared to the no drug control in all combinations except those 
involving artemisinin, hydroxychloroquine and fluconazole. It is possible that the 
similarity between the antibacterial mechanisms of these drugs for both membrane and 
intracellular damage resulted in competition for the drug targets rather than additive 
benefit. As with previously discussed combinations, free radical producing methylene 
blue has high activity in combination with cell wall disruptors and protein synthesis 
inhibitors such as doxycycline. However, methylene blue also appears to work well in 
combination with transcription inhibitors such as rifabutin, rifaximin and ciprofloxacin. 
However, these DNA transcription inhibitors did not have high antibacterial activity 
when used with other free radical producing drugs. This suggests that methylene blue 
may cause more oxidative damage to non-protein targets than either artemisinin or 
nitrofurantoin, as DNA transcription will have cellular effects beyond protein synthesis 





possible that methylene blue’s exclusive ability to modify guanine residues is the cause 
of this extra damage.  
Table 8. Proportion of viable and killed cells after 7-day treatment with high activity 
azithromycin-containing combinations against stationary phase Borrelia burgdorferi 
when compared to no drug control 















No Drug Control 0 1.00 0.00 ---   
 
  
Amoxicillin 5 0.97 0.03 0.05      








Methylene Blue + Drug treatment 
Cefuroxime + 

















Azithromycin 2 0.88 0.12 0.11 0.64 0.36 0.13 
Pyrimethamine 2 0.81 0.19 0.06 0.69 0.31 0.08 
Rifaximin 2 0.86 0.14 0.04 0.69 0.31 0.22 
Nitrofurantoin 2 0.85 0.15 0.01 0.72 0.28 0.09 
Rifabutin 2 >0.9 <0.1 --- 0.75 0.25 --- 
Ciprofloxacin 3 0.84 0.16 0.07 0.77 0.23 0.20 
Doxycycline 3 0.85 0.15 0.11 0.82 0.18 0.00 
Clofazimine 2 0.88 0.12 0.13 >0.9 <0.1 --- 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 





standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
  Many drug combinations containing methylene blue had high activity against 
both stationary phase and persistent populations. Interestingly, while the addition of 
cefuroxime increases the anti-persister activity of most of the combinations, it appears to 
lessen the activity of combinations including rifabutin (Table 9). Rifabutin inhibits the 
DNA transcription mechanism.63 The highly lipophilic nature of these drugs may allow 
for efficient cell permeability without the need for cell wall disruption in the persistent 
population. Cefuroxime’s intracellular presence may also block rifabutin’s ability to 
effectively bind to and inhibit DNA transcription mechanisms.63 While rifabutin anti-
persister function does not require cell wall disruption, less lipophilic drugs may require 















Table 9. Proportion of viable and killed cells after 7-day treatment with high activity 
methylene blue-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 













No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.78 0.22 0.27      








Methylene Blue + Drug treatment 
Cefuroxime + 

















Rifabutin 2 0.59 0.41 --- 0.76 0.24 --- 
Ciprofloxacin 3 0.90 0.10 0.22 0.76 0.24 0.14 
Nitrofurantoin 2 0.74 0.26 0.12 0.78 0.22 0.09 
Rifaximin 2 0.86 0.14 0.27 0.79 0.21 0.25 
Azithromycin 2 0.80 0.20 0.23 0.80 0.20 0.15 
Doxycycline 3 0.85 0.15 0.26 0.83 0.17 0.15 
Artemisinin 2 >0.9 <0.1 --- 0.84 0.16 0.25 
Hydroxychloroquine 2 0.87 0.23 0.31 0.88 0.12 0.21 
Clofazimine 2 0.88 0.12 0.19 0.88 0.12 0.20 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 






Highly Effective Drugs against Persistent Borrelia When Used in Combination 
 
Doxycycline 
 Doxycycline is a tetracycline derivative protein synthesis inhibitor with 
widespread activity against both gram positive and gram negative bacteria.71 Doxycycline 
binds to the bacterial ribosome and inhibits the ribosomal binding of aminoacyl t-RNA, a 
necessary step in the initiation of protein synthesis.72 Doxycycline is a commonly used 
antibiotic against early stage Lyme disease, but has not been found to be effective against 
stationary phase Borrelia when used individually.34 However, when added in 
combination with methylene blue, doxycycline has high activity against stationary phase 
populations, as has been seen with other free radical producing and protein synthesis 
inhibiting drug combinations (Table 10). 
Doxycycline does, however, has high activity against persistent populations in 
triple drug combinations including cefuroxime and either rifabutin or ciprofloxacin, both 
drugs involved in inhibition of RNA synthesis (Table 11). Ciprofloxacin binds directly to 
DNA, preventing binding of DNA gyrase and not allowing the DNA to form a negative 
superhelix.73,74 RNA synthesis inhibitors affect the ability of the cell to regulate gene 
expression and also prevent protein synthesis. It is likely that the combination of 
doxycycline and a RNA synthesis inhibitor are able to synergistically inhibit protein 







Table 10. Proportion of viable and killed cells after 7-day treatment with high activity 
doxycycline-containing combinations against stationary phase Borrelia burgdorferi when 
compared to no drug control 
















0 1.00 0.00 ---   
 
  
Amoxicillin 5 0.97 0.03 0.05      








Doxycycline + Drug treatment 
Cefuroxime + 




















4 >0.9 <0.1 0.11 0.82 0.18 0.00 
Artemisinin 2 >0.9 <0.1 --- 0.85 0.15 0.20 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 









Table 11. Proportion of viable and killed cells after 7-day treatment with high activity 
doxycycline-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 















0 1.00 0.00 ---   
 
  
Amoxicillin 5 0.78 0.22 0.27      








Doxycycline + Drug treatment 
Cefuroxime + 

















Rifabutin 2 >0.9 <0.1 --- 0.58 0.42 --- 
Ciprofloxacin 3 >0.9 <0.1 --- 0.77 0.23 0.26 
Pyrimethamine 2 0.81 0.19 0.13 >0.9 <0.1 --- 
Methylene Blue 4 0.85 0.15 0.26 0.83 0.17 0.15 
Artemisinin 2 >0.9 <0.1 --- 0.86 0.14 0.15 
Fluconazole 6 >0.9 <0.1 --- 0.87 0.13 0.23 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 










 Hydroxychloroquine is chloroquine derivative that is believed to function by 
altering cellular metabolism.75 Though used commonly against malarial infections, the 
exact mechanism for action against prokaryotes is still undetermined, as its primary target 
in eukaryotic cells are membrane-bound vesicles, which inhibits the parasite’s ability to 
break down hemoglobin.75 Hydroxychloroquine is a highly penetrative weak lipophilic 
base that is able to penetrate through plasma membranes and accumulate intracellularly in 
eukaryotes. Therefore the drug may be able to penetrate the bacterial cell membrane and 
accumulate within the cytoplasm.76 Once intracellular, hydroxychloroquine’s alkaline 
nature attracts acids into the cytoplasm, which can alter the ion gradient, prevent efficient 
nutrient uptake and destabilize bacterial enzymes.76 The presence of permeant bases such 
as hydroxychloroquine can rapidly overwhelm the bacterial internal pH homeostasis 
mechanisms and effect DNA integrity and bacterial protein structure.68  
 Hydroxychloroquine only has activity against stationary phase Borrelia 
populations when used in combination with free radical producing and protein synthesis 
inhibiting drugs (Table 12) This increase in activity is likely due to a decrease in 
intracellular pH affecting both DNA and protein structure. Genes implicated in the 
maintenance of DNA stability have also been found to be upregulated in doxycycline-
induced persistent Borrelia populations, suggesting this is an important mechanism for 







Table 12. Proportion of viable and killed cells after 7-day treatment with high activity 
hydroxychloroquine-containing combinations against stationary phase Borrelia 
burgdorferi when compared to no drug control 










   
No Drug Control 0 1.00 0.00 ---      
Amoxicillin 5 0.97 0.03 0.05      




10 0.64 0.36 ---      
 




















Azithromycin 2 >0.9 <0.1 --- 0.80 0.20 0.01 
Artemisinin 2 >0.9 <0.1 --- 0.88 0.12 0.04 
Nitrofurantoin 2 >0.9 <0.1 --- 0.90 0.10 0.03 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
The high activity hydroxychloroquine-containing drug combinations against 
persistent populations were involved in inhibiting metabolism and DNA transcription 
(Table 13). In fact, the triple combination of hydroxychloroquine, cefuroxime and 





previously discussed, nutrient uptake has been shown to be an upregulated process in 
both doxycycline and amoxicillin treated persister cells, suggesting its importance in the 
maintenance of persisters. It is possible that the alteration of the intracellular pH 
disrupted the ion transport gradient, preventing the cells from achieving the necessary 
nutrients in their dormant state. When coupled with drugs that alter DNA transcription, 
transmembrane proteins may also be affected, further preventing the cells from 
maintaining their necessary nutrient and ion balance.77 This would also explain why 
fluconazole was effective in combination with cefuroxime and hydroxychloroquine, as 
















Table 13. Proportion of viable and killed cells after 7-day treatment with high activity 
hydroxychloroquine-containing combinations against amoxicillin-treated persistent 
Borrelia burgdorferi when compared to no drug control 










   
No Drug 
Control 
0 1.00 0.00 ---      
Amoxicillin 5 0.78 0.22 0.27      




10 0.42 0.58 ---      
 
Azithromycin + Drug treatment 
Cefuroxime + 

















Rifabutin 2 0.65 0.35 --- 0.57 0.43 --- 
Fluconazole 6 >0.9 <0.1 --- 0.72 0.28 0.16 
Pyrimethamine 2 >0.9 <0.1 --- 0.77 0.23 0.22 
Azithromycin 2 >0.9 <0.1 --- 0.80 0.20 0.28 
Artemisinin 2 >0.9 <0.1 --- 0.85 0.15 0.30 
Rifaximin 2 >0.9 <0.1 --- 0.86 0.14 0.28 
Methylene Blue 4 0.87 0.13 0.31 0.88 0.12 0.21 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 








 Rifabutin is a spiro-piperidyl-rifampin derivative that inhibits DNA transcription 
by binding to the beta-subunit of the DNA-RNA polymerase.63 Rifabutin is one of the 
most lipophilic and highly penetrative rifampin derivatives, allowing for increased 
intracellular penetration over rifaximin, another rifampin derivative used in the screen.63 
The prevention of RNA synthesis can result in an inhibition of protein synthesis as well 
as prevent the cell from regulating gene expression. Amoxicillin-treated Borrelia 
persisters have been shown to upregulate 342 genes and downregulate 174 genes 
compared to non-treated Borrelia populations.60 Without the ability to regulate gene 
expression in response to this drug-induced stress, the bacteria will likely be less able to 
maintain its persistent state. 
Rifabutin does best against stationary phase bacteria when used when in 
combination with free radical producing and protein synthesis inhibiting drugs (Table 
14). This increase in antibacterial activity is likely due to an additive effect on protein 
inhibition, as these drugs would all damage proteins at different stages in the production 
process. This would allow for a more complete inhibition of protein synthesis without 









Table 14. Proportion of viable and killed cells after 7-day treatment with high activity 
rifabutin-containing combinations against stationary phase Borrelia burgdorferi when 
compared to no drug control 















0 1.00 0.00 --- 
 
Amoxicillin 5 0.97 0.03 0.05  




10 0.64 0.36 --- 
 
 
Rifabutin + Drug treatment 
Cefuroxime + 














Nitrofurantoin 2 >0.9 <0.1 0.75 0.25 
Methylene 
Blue 
4 >0.9 <0.1 0.75 0.25 
Azithromycin 2 >0.9 <0.1 0.78 0.22 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 
replicate, and therefore do not have an accompanying standard error, represented by “---
“.  
 Rifabutin containing combinations have some of the highest activity against 





decrease protein stability and function (Table 15). While rifabutin-containing 
combinations have higher antibacterial activity when combined with cefuroxime, 
methylene blue and fluconazole have lower antibacterial activity when used with the 
drug. Both of these drugs have high activity on the bacterial membrane. It is possible that 
the addition of cefuroxime may hinder the activity of drugs that interact with the plasma 
membrane either as a drug target or for penetration into the cell. Cefuroxime’s disruptive 
effect on the bacterial cell wall could result in changes in the Borrelia plasma membrane, 
especially if the cell wall becomes perforated. This change in the cell wall could alter 
aspects of the plasma membrane making it harder for the other drugs to act on the lipids.  
 Rifabutin has high activity against amoxicillin-treated Borrelia persisters when in 
combination with many different drugs. Rifabutin’s inhibition of RNA synthesis likely 
has an additive effect when used in combination with cefuroxime, nitrofurantoin, and 
doxycycline, which act on the protein synthesis pathway. This follows a trend seen with 
other drug combinations that suggests protein synthesis may be a key pathway to target 
against Borrelia persisters. The high activity of rifabutin with fluconazole and 
hydroxychloroquine also suggests that regulation of cellular homeostasis and nutrient 
transport could also be a key target for persistent Borrelia. By inhibiting the ability of the 
cell to regulate gene expression, the bacteria will likely be unable to adequately cope with 
stressors such as increased intracellular pH, nutrient imbalance or the oxidative damage 







Table 15. Proportion of viable and killed cells after 7-day treatment with high activity 
rifabutin-containing combinations against amoxicillin-treated persistent Borrelia 
burgdorferi when compared to no drug control 











No Drug Control 0 1.00 0.00 ---  
Amoxicillin 5 0.78 0.22 0.27  




10 0.42 0.58 ---  
 
Rifabutin + Drug treatment 
Cefuroxime + 












Hydroxychloroquine 2 0.65 0.35 0.57 0.43 
Nitrofurantoin 2 >0.9 <0.1 0.57 0.43 
Doxycycline 3 >0.9 <0.1 0.58 0.42 
Methylene blue 4 0.59 0.41 0.76 0.24 
Fluconazole 6 0.63 0.37 >0.9 <0.1 
Artemisinin 2 >0.9 <0.1 0.69 0.31 
*Viability of residual cells remaining after drug treatment determined via epifluorescent 
microscopy. Drug combinations that showed high activity in the SYBR Green I/PI rapid 
viability test were examined microscopically for residual viable cells remaining after 
treatment. The average of triplicate microscopic values was taken for each high activity 
combination. These drug combinations were repeated against a different Borrelia 
burgdorferi culture and a second average residual viable cells remaining value was 
determined. The average residual viable cells remaining for each biological replicate was 
transformed into a proportion of residual viable cells remaining in comparison to the 
replicate’s no drug control value to account for inter-plate variation. The average of these 
two proportions are presented with accompanying standard error. The no drug control 
standard is shown as a proportion of 1.00, equating to a 100% viable cell baseline against 
which all drug combinations were measured. Some drugs were only tested against one 









 The drug combination of daptomycin + doxycycline + cefoperazone has been 
found to be highly active against an in vitro persister model using stationary phase 
Borrelia.35 In this study, this drug combination was found to be highly effective against 
both stationary phase and amoxicillin-treated persisters. However, there were drug 
combinations consisting of better tolerated and orally available drugs that had similar 
activity against these Borrelia populations in vitro. These highly active drug 
combinations can provide insight into better treatment of Borrelia in vitro by identifying 
key pathway combinations to target for future treatments. The drug combinations with 
the highest activity against stationary phase populations were drug combinations of free 
radical producing drugs along with protein synthesis inhibitors and cell wall disruptors, 
including; cefuroxime + artemisinin + azithromycin, cefuroxime + methylene blue + 
azithromycin, cefuroxime + methylene blue + nitrofurantoin, and cefuroxime + 
artemisinin + nitrofurantoin.  
The addition of cefuroxime to the drug combinations generally helped the 
antibacterial activity of these combinations against stationary phase populations, with a 
few exceptions. This data seems to suggest that cell wall penetration is a key aspect for 
drug treatment against stationary phase Borrelia in vitro. However, drugs associated with 
plasma membrane phospholipids such as hydroxychloroquine and fluconazole had higher 
activity against persisters, suggesting that membrane permeability may play a more 
important role in killing of persisters than stationary phase Borrelia.  
The drug combinations with the highest activity against amoxicillin-treated 





synthesis inhibitors or intracellular homeostasis regulators. These combinations included: 
cefuroxime + rifabutin + hydroxychloroquine, cefuroxime + nitrofurantoin + rifabutin, 
cefuroxime + doxycycline + rifabutin, and rifabutin + fluconazole. The combinations 
with the highest activity against persistent Borrelia contained drugs that affected DNA 
integrity and nutrient uptake, such as hydroxychloroquine, fluconazole, and 
ciprofloxacin, rather than protein maintenance. 
However, the definitive mechanism of action of these drugs has not been 
determined against persistent Borrelia. More research needs to be done to confirm the 
mechanisms of these drugs within these populations. More replicates will also need to be 
done of these drug combinations for further confirmation of the drug combination’s 
activity in vitro. These drug combinations would need further study both in vitro and in 
vivo in animal models before use in the clinic. However, this study does suggest that 
optimal treatment of Lyme patients may be different for untreated and treatment-resistant 
PTLDS patients. Overall, the use of combination therapy of readily available oral drugs 
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